How would you select patients for epcoritamab + R² versus R² or other regimens at second-line relapsed/refractory follicular lymphoma?

It depends on what they received as first-line therapy and the duration of response to that treatment. The disease burden at the time of relapse would also be a key factor. The rate of infections was notably higher in the epcor + R² group. In the subgroup analysis, the benefit amongst older patients...

We discuss all options, including logistics, safety, tolerability, and efficacy. We discuss that this is the regimen with the longest and deepest responses for a 2nd line-fixed-duration therapy. It is also chemo-free.

In second-line relapsed/refractory follicular lymphoma, I would now view epcoritamab + R² as the preferred option for many patients who are appropriate for active immunotherapy and can tolerate the added cytopenia/infection monitoring. The EPCORE FL-1 data are compelling: ORR 95% vs 79%, CR 83% vs 5...